These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33209172)

  • 1. Treatment outcomes and factors associated with unfavourable outcome among previously treated tuberculosis patients with isoniazid resistance in four regions of Cameroon.
    Kuaban C; Toukam LDI; Sander M
    Pan Afr Med J; 2020; 37():45. PubMed ID: 33209172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and factors associated with unfavourable treatment outcome among patients with rifampicin-resistant pulmonary tuberculosis in Yaoundé, Cameroon.
    Kuaban A; Balkissou AD; Ekongolo MCE; Nsounfon AW; Pefura-Yone EW; Kuaban C
    Pan Afr Med J; 2021; 38():229. PubMed ID: 34046134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis.
    Thai PVK; Ha DTM; Hanh NT; Day J; Dunstan S; Nhu NTQ; Kiet VS; Lan NH; Dung NH; Lan NTN; Thuong NT; Lan NN; Liễu PTT; Hồng NT; Điệp ĐC; Thanh NTK; Hội NV; Nghĩa NV; Đại TN; Minh HQ; Thơm NV; Farrar J; Caws M
    BMC Infect Dis; 2018 Mar; 18(1):112. PubMed ID: 29510687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The therapeutic effect of regimens containing isoniazid and rifampicin for pulmonary tuberculosis with single isoniazid or rifampicin resistance].
    Tan S; Ding X; Tan Y; Cai X; Li Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):915-8. PubMed ID: 25609129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mycobacterial drug resistance patterns on patients' survival: a cohort study in Thailand.
    Anuwatnonthakate A; Whitehead SJ; Varma JK; Silachamroon U; Kasetjaroen Y; Moolphate S; Limsomboon P; Inyaphong J; Suriyon N; Kavinum S; Chiengson N; Tunteerapat P; Kaewkungwal J
    Glob J Health Sci; 2013 Aug; 5(6):60-72. PubMed ID: 24171875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of isoniazid-monoresistant tuberculosis (Hr-TB) in Queensland, Australia: a retrospective case series.
    Wilson M; O'Connor B; Matigian N; Eather G
    Respir Med; 2020 Nov; 173():106163. PubMed ID: 33002798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study.
    Abanda NN; Djieugoué JY; Lim E; Pefura-Yone EW; Mbacham WF; Vernet G; Penlap VM; Eyangoh SI; Taylor DW; Leke RGF
    BMC Infect Dis; 2017 May; 17(1):379. PubMed ID: 28569148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon.
    Noeske J; Voelz N; Fon E; Abena Foe JL
    BMC Res Notes; 2012 Mar; 5():160. PubMed ID: 22436423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
    Cornejo Garcia JG; Alarcón Guizado VA; Mendoza Ticona A; Alarcon E; Heldal E; Moore DAJ
    PLoS One; 2018; 13(12):e0206658. PubMed ID: 30513085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Analysis of Prevalence and Risk Factors of Rifampicin-Resistant Tuberculosis in Zhejiang, China.
    Liu Z; Zhang M; Wang J; Chen S; Wu B; Zhou L; Pan A; Wang W; Wang X
    Biomed Res Int; 2020; 2020():3159482. PubMed ID: 32104686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010.
    Báez-Saldaña R; Delgado-Sánchez G; García-García L; Cruz-Hervert LP; Montesinos-Castillo M; Ferreyra-Reyes L; Bobadilla-Del-Valle M; Canizales-Quintero S; Ferreira-Guerrero E; Téllez-Vázquez N; Montero-Campos R; Yanes-Lane M; Mongua-Rodriguez N; Martínez-Gamboa RA; Sifuentes-Osornio J; Ponce-de-León A
    PLoS One; 2016; 11(12):e0168955. PubMed ID: 28030600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing.
    Kim S; Lee H; Park HY; Jeon K; Huh HJ; Lee NY; Jeong BH
    Respir Med; 2017 Dec; 133():6-11. PubMed ID: 29173450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment.
    Abate D; Tedla Y; Meressa D; Ameni G
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):946-51. PubMed ID: 25199009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of culture-confirmed isoniazid-resistant rifampicin-susceptible tuberculosis in children.
    Garcia-Prats AJ; du Plessis L; Draper HR; Burger A; Seddon JA; Zimri K; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2016 Nov; 20(11):1469-1476. PubMed ID: 27776587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
    Wada M
    Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.